Cimerli 0.5 mg/0.05 mL (10 mg/mL) intravitreal injection Images
Generic Name: ranibizumab
This medication has been identified as Cimerli 0.5 mg/0.05 mL (10 mg/mL) intravitreal injection and is used for Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Myopic Choroidal Neovascularization. It belongs to the drug class anti-angiogenic ophthalmic agents and is not a controlled substance.
Images of medication
Cimerli
- Generic Name
- ranibizumab
- Strength
- 0.5 mg/0.05 mL (10 mg/mL) intravitreal injection
- Availability
- Prescription only
- Drug Class
- Anti-angiogenic ophthalmic agents
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Coherus BioSciences, Inc.
- National Drug Code (NDC)
- 70114-0441
See also:
More about Cimerli (ranibizumab ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-angiogenic ophthalmic agents
- Breastfeeding
- En español
Patient resources
- Cimerli drug information
- Cimerli ophthalmic
- Cimerli (Ranibizumab Intraocular) (Advanced Reading)
- Cimerli (Ranibizumab-eqrn Intraocular) (Advanced Reading)
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.